Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What are your key takeaways regarding the difference in findings for BETA-MI DANBLOCK and REBOOT in patients post-MI with LVEF >40%?
Related Questions
What are your preferred femoral vascular closure devices for severely calcified femoral artery vessels following PCI, especially with higher sticks, and why?
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
When is a reasonable amount of time for patients to be on 90 mg BID of ticagrelor before transitioning to 60 mg BID following PCI?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
Do you recommend stepwise de-escalation of dual antiplatelet therapy for patients at high risk of bleeding who have undergone drug-coated balloon angioplasty?
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Do you always give 325mg aspirin if not already loaded with antiplatelets prior to the start of every LHC, even just for diagnostics in the absence of ACS?
What is your stepwise approach to managing no re-flow during PCI?
